title: Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
abstract: This prospective non-interventional study assessed the management of relapsed/refractory CLL after one or two treatments with rituximab, and retreatment with a rituximab-based regimen. An interim analysis was performed at the end of the induction period in 192 evaluable patients. Median age was 72 years [35-89], first relapse (55%), and second relapse (45%). Rituximab administered during first (68%), second (92%), or both treatment lines (20%). R-bendamustine administered in 56% of patients, R-purine analogs (21%), and R-alkylating agents (19%). The overall response rate (ORR) was 74.6%, in favor of R-purine analogs (90%), R-bendamustine (75%), and R-alkylating agents (69%). Lower ORR in Del 17p patients (43%) and third time rituximab (31%). Most frequent adverse events were hematological (23% patients) including neutropenia (11%) and infections (12%); grade 3/4 AEs (23% patients), mainly hematological (18%); death during induction treatment (7%). This first large study focusing on relapsed/refractory CLL patients retreated with rituximab-based regimens is still ongoing.
authors.affiliation: a Hématologie, Centre hospitalier Victor Dupouy , Argenteuil , France.
authors.forename: Driss
authors.initials: D
authors.lastname: Chaoui
authors.affiliation: b Hématologie, Hôpital La Pitié Salpêtrière , Paris , France.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Choquet
authors.affiliation: c Hématologie, Hôpital Saint-Jean , Perpignan , France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Sanhes
authors.affiliation: d Hématologie, CHU de Nantes , Nantes , France.
authors.forename: Béatrice
authors.initials: B
authors.lastname: Mahé
authors.affiliation: e Hématologie, Centre hospitalier de Chambéry , Chambéry , France.
authors.forename: Maya
authors.initials: M
authors.lastname: Hacini
authors.affiliation: f Hématologie, Polyclinique Bordeaux Nord , Bordeaux , France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Fitoussi
authors.affiliation: g Hématologie, Hôpital Emile Muller , Mulhouse , France.
authors.forename: Yazid
authors.initials: Y
authors.lastname: Arkam
authors.affiliation: h Hématologie, Centre hospitalier de Fleyriat , Bourg en Bresse , France.
authors.forename: Hubert
authors.initials: H
authors.lastname: Orfeuvre
authors.affiliation: i Hématologie, Hôpitaux de Bordeaux Pessac, Hôpital Haut Levêque , France.
authors.forename: Marie-Sarah
authors.initials: MS
authors.lastname: Dilhuydy
authors.affiliation: j Hématologie, Centre hospitalier du Dr Duchenne , Boulogne sur Mer , France.
authors.forename: Marly
authors.initials: M
authors.lastname: Barry
authors.affiliation: k Hématologie, CHU de Nîmes , Nîmes , France.
authors.forename: Eric
authors.initials: E
authors.lastname: Jourdan
authors.affiliation: l Hématologie, Pôle Régional de Cancérologie , Poitiers , France.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dreyfus
authors.affiliation: m Hématologie, Hôpital Auguste Morvan , Brest , France.
authors.forename: Adrian
authors.initials: A
authors.lastname: Tempescul
authors.affiliation: n Hématologie, Centre Henri Becquerel , Rouen , France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Leprêtre
authors.affiliation: o Medical Affairs, Roche France , Boulogne-Billancourt , France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Bardet
authors.affiliation: o Medical Affairs, Roche France , Boulogne-Billancourt , France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Leconte
authors.affiliation: p Hématologie, CHU du Bocage , Dijon , France.
authors.forename: Marc
authors.initials: M
authors.lastname: Maynadié
authors.affiliation: q Hématologie, CHU Robert Debré , Reims , France.
authors.forename: Alain
authors.initials: A
authors.lastname: Delmer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019233:Retreatment; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000069283:Rituximab
keywords: Chronic lymphocytic leukemia; chemotherapy; relapsed/refractory CLL; rituximab